-
Drug Discovery & Therapeutics1 month agoLilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of...
-
Drug Discovery & Therapeutics1 month agoSuppressor tRNAs take two translational steps forward
BIOCENTURY | DISCOVERY & TRANSLATIONSUPPRESSOR TRNAS TAKE TWO TRANSLATIONAL STEPS FORWARDPreclinical Duchenne and cystic fibrosis studies point to ways around two of the modality’s most stubborn...
-
Drug Discovery & Therapeutics2 months agoCyclic peptides open new drug frontiers, if manufacturing can keep up
With oral cyclic peptides offering small molecule convenience and antibody‑like selectivity, the modality is gaining momentum. But bioavailability below 1%, minimal PK data and fragile synthesis...
-
Drug Discovery & Therapeutics2 months agoCarbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
A new comprehensive review published in the Journal of Nanoparticle Research surveys one of the most quietly promising corners of nanomedicine: carbon dots, nanoscale specks of...
-
Drug Discovery & Therapeutics2 months agoAzithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, remains the second most prevalent bacterial sexually transmitted infection worldwide and has become a central figure in the escalating...
-
Drug Discovery & Therapeutics2 months agoConsiderations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing – 09/14/2026
The Food and Drug Administration is announcing a public hearing on the potential future therapeutic use of psychedelic drugs.
-
Drug Discovery & Therapeutics2 months agoBone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior
By reproducing elements of human bone marrow on a chip, scientists have created a new tool that will help them gain new insights into how immune...
-
Drug Discovery & Therapeutics2 months agoSTAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
-
Drug Discovery & Therapeutics2 months agoTranscenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology
Transcenta, headquartered in China and with a pipeline of over ten therapeutic antibody candidates, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research,...
-
Drug Discovery & Therapeutics2 months agoDisc sets up polycythemia vera challenge but Silence maintains lead
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
